Sertraline (Zoloft) and Restless Legs Syndrome
Yes, sertraline can cause or worsen restless legs syndrome (RLS), though this occurs in a minority of patients—approximately 5-10% based on prospective data. 1
Evidence for Sertraline-Induced RLS
The FDA label for Zoloft does not specifically list RLS as a known adverse effect 2, but clinical research demonstrates a clear association:
Prospective polysomnography studies show sertraline increases periodic limb movements during sleep (PLMS), with the PLMI rising from baseline 3.6 to 8.5 after 8 weeks of treatment 3. This effect appears dose-dependent and stabilizes after 2 weeks of treatment.
Systematic reviews indicate sertraline causes periodic limb movements that typically do not disrupt sleep and are thus unlikely to be clinically significant in most patients 4.
A large symmetry analysis of 10,875 Danish patients found no overall increased risk of RLS drug initiation after starting SSRIs, though a modest signal existed for dopamine agonist prescriptions (adjusted SR 1.21) 5.
Prospective observational data from neurological practices found RLS occurred as a side effect in 5-10% of patients on sertraline, typically within the initial days of treatment 1.
Management Algorithm
Step 1: Confirm Drug-Induced RLS
- Verify symptoms started within days to weeks of sertraline initiation or dose increase
- Rule out mimicking conditions (peripheral neuropathy, venous insufficiency, akathisia)
- Check if symptoms meet diagnostic criteria: urge to move legs, worse at rest/evening, relieved by movement
Step 2: Assess Iron Status FIRST
Check ferritin and transferrin saturation before any other intervention 6:
- If ferritin <75 ng/mL or transferrin saturation <20%, treat with ferrous sulfate (conditional recommendation, moderate certainty) 6
- Consider IV ferric carboxymaltose for appropriate iron parameters (strong recommendation, moderate certainty) 6
Step 3: Modify Antidepressant Strategy
If RLS persists despite iron optimization:
Switch to bupropion, which may actually reduce RLS symptoms rather than cause them 4. The 2025 AASM guidelines specifically recommend against bupropion for treating RLS 6, but research shows it doesn't induce RLS and may improve symptoms.
Alternative non-RLS-inducing antidepressants:
- Trazodone (though one case report exists 7, systematic reviews show it doesn't aggravate PLMS 4)
- Nefazodone or doxepin (sedating antidepressants that don't worsen PLMS 4)
Avoid mirtazapine, which has the highest rate of RLS induction (28% of patients) 1.
Step 4: Treat RLS if Antidepressant Cannot Be Changed
If sertraline must be continued for psychiatric reasons, treat the RLS according to 2025 AASM guidelines 6:
First-line options (strong recommendations):
- Gabapentin enacarbil (600-1200 mg nightly)
- Gabapentin (300-1800 mg nightly)
- Pregabalin (150-450 mg nightly)
Second-line options (conditional recommendations):
Avoid dopamine agonists (pramipexole, ropinirole, rotigotine) as standard treatment due to augmentation risk with long-term use 6.
Critical Caveats
The sertraline-induced PLMS may have a higher arousal index (9.4 vs 5.2 in non-PLMS patients) even when not causing overt clinical symptoms 3, potentially affecting sleep quality.
RLS symptoms typically appear within the first few days of starting sertraline 1, making temporal association easier to establish.
Do not abruptly discontinue sertraline without psychiatric consultation due to discontinuation syndrome risk (anxiety, irritability, electric shock sensations, dizziness) 2.
The evidence shows sertraline increases PLMS more than it causes clinically significant RLS—many patients have elevated leg movements on polysomnography without subjective symptoms 3, 4.